From: Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
N (%) | Anti-acid medication at baseline | No anti-acid medication at baseline | ||
---|---|---|---|---|
Nintedanib (n = 244) | Placebo (n = 162) | Nintedanib (n = 394) | Placebo (n = 261) | |
Absolute decline in FVC ≥10% predicted or death | 77 (31.6) | 77 (47.5) | 96 (24.4) | 98 (37.5) |
Criterion reached first | ||||
Absolute decline in FVC ≥10% predicted | 67 (27.5) | 65 (40.1) | 81 (20.6) | 88 (33.7) |
Death | 10 (4.1) | 12 (7.4) | 15 (3.8) | 10 (3.8) |
Absolute decline in FVC ≥5% predicted or death | 135 (55.3) | 122 (75.3) | 195 (49.5) | 181 (69.3) |
Criterion reached first | ||||
Absolute decline in FVC ≥5% predicted | 129 (52.9) | 117 (72.2) | 188 (47.7) | 175 (67.0) |
Death | 6 (2.5) | 5 (3.1) | 7 (1.8) | 6 (2.3) |